OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219

OnKure Therapeutics, Inc.

2026-Q1 EPS reported -$1.11

Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
Cash and cash equivalents $192.1M as of March 31, 2026, including $150M private placement closed on March 31, expected to fund operations into 2029.
Announced nomination of OKI-355 for vascular anomalies and OKI-345 for breast cancer; IND submissions planned for first half 2027.
Company will not independently pursue further clinical development of OKI-219; data from PIKture-01 study to be reported by end of 2026.
R&D expenses $11.7M (down from $13.0M), G&A $3.9M (down from $4.0M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OnKure Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.